Inhaled Antibiotics Market, by Product Type (Aerosol, Dry Powder Formulation, and Spray), by Application (Pneumonia, Asthma, Bronchitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI3980

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Inhaled Antibiotics Market: Key Developments

In November 2022, Lupin Ltd.,, an Indian multinational pharmaceutical company, based in India, announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial, to market a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

In August 2021, Philip Morris International Inc, a U.S.-based Tobacco company, acquired OtiTopic for an undisclosed amount. This acquisition is part of PMI's strategic objective to expand its pipeline of inhaled therapies and respiratory medication delivery by using its expertise, scientific know-how, and inhalation capabilities apart from nicotine. OtiTopic is a U.S.-based respiratory drug development company including inhaled antibiotics.

In July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms.